Funds holding BIONEXUS GENE LAB CORP
ISIN US0906283066 · United States · LEI 549300COYSKRA3Z7E531
- Fund holders
- 2
- Of which ETFs
- 0 2 other funds
- Value held
- 5.5K $
- Share of capital
- 0.1 % of 2.9M shares on Aug 14, 2026
2 tracked funds declare this company. So these figures do not say who owns it.
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 2,368 | 5.5K $ | 0.08 % | as of May 31, 2026 ↗ | |
| Blackstone Alternative Multi-Strategy Fund Blackstone Alternative Investment Funds | 3 | 5.9 $ | 0.00 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 2 | 0 | 2,371 | 0.0 % |
| 2026Q2 | 2 | 0 | 2,371 | 0.0 % |
| 2026Q1 | 2 | 0 | 2,371 | 0.0 % |
| 2025Q4 | 2 | 0 | 2,371 | 0.0 % |
| 2025Q3 | 2 | 2,371 |
Institutional managers
2 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| UBS Group AG | 231 | 495 $ | as of Mar 31, 2026 |
| WELLS FARGO & COMPANY/MN | 1 | 2 $ | as of Mar 31, 2026 |
Declared shareholders of BIONEXUS GENE LAB CORP
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Tan Lee Su-Leng | 11.50 % | 338,709 | as of Aug 13, 2026 · SCHEDULE 13D |
Cite this page
Titelia. "Funds holding BIONEXUS GENE LAB CORP". https://titelia.com/en/stocks/bionexus-gene-lab-corp-US0906283066